HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137. doi:10.1038/3505207311252954
   PubMed Web of Science ®Google Scholar
• Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21(2):100–107. doi:10.1097/PAP.000000000000001524508693
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697; PMID: 20728210. doi: 10.1016/S0140-6736(10)61121-X20728210
   PubMed Web of Science ®Google Scholar
• Miller K, Cortes J, Hurvitz SA, et al. A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016;16(1):352. PMID: 27259714; PMCID: PMC4893300. doi:10.1186/s12885-016-2385-z.27259714
   PubMed Web of Science ®Google Scholar
• Greally M, Kelly CM, Cercek A. HER2: an emerging target in colorectal cancer. Curr Probl Cancer. 2018;42(6):560–571. doi:10.1016/j.currproblcancer.2018.07.00130100092
   PubMed Web of Science ®Google Scholar
• Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–570. doi:10.1002/path.467926690310
   PubMed Web of Science ®Google Scholar
• De Cuyper A, Van Den Eynde M, Machiels JP. HER2 as a predictive biomarker and treatment target in colorectal cancer. Clin Colorectal Cancer. 2020;19(2):65–72. doi:10.1016/j.clcc.2020.02.00732229076
   PubMed Web of Science ®Google Scholar
• Lee W-S, Park YH, Lee JN, et al. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3(3):674–680. doi:10.1002/cam4.22824668895
   PubMed Web of Science ®Google Scholar
• Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6(1):123. doi:10.1186/1471-2407-6-12316681853
   PubMed Web of Science ®Google Scholar
• Karahan B, Argon A, Yıldırım M, Vardar E. Relationship between MLH-1, MSH-2, PMS-2, MSH-6 expression and clinicopathological features in colorectal cancer. Int J Clin Exp Pathol. 2015;8(4):4044–4053. PMID: 26097592; PMCID: PMC4466979.26097592
   PubMed Web of Science ®Google Scholar
• Kumar V. Robbins and Cotran Pathologic Basis of Disease. Kumar V, Abbas AK, Fausto N, editors. Philadelphia PA: Elsevier Saunders; 2005:269–342.
   Google Scholar
• Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer. 2005;4(3):211–218. doi:10.1007/s10689-004-4489-x16136380
   PubMed Web of Science ®Google Scholar
• Delahunty R, Mcmurrick P, Carne P, et al. Screening for mismatch repair deficiency in colorectal cancer[J]. Asia Pac Clin Oncol. 2015;11(S3):52.
   Google Scholar
• Ramchander NC, Ryan NA, Crosbie EJ, Evans DG. Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD). BMC Med Genet. 2017;18(1):40. doi:10.1186/s12881-017-0391-x28381238
   PubMed Web of Science ®Google Scholar
• Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Gastroenterology. 2017;153(1):307–323. doi:10.1053/j.gastro.2017.05.01328600072
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge SB, Greene FL, et al.; Organization of the AJCC Cancer Staging Manual. AJCC Cancer Staging Manual; 2017
   Google Scholar
• Editing group for guidelines for the detection of HER2 in gastric cancer. Guidelines for HER2 detection in gastric cancer. Chin J Pathol. 2011;40(8):553–557.
   Google Scholar
• Li C, Liu DR, Ye LY, et al. HER-2 overexpression and survival in colorectal cancer: a meta-analysis. J Zhejiang Univ Sci B. 2014;15(6):582–589. doi:10.1631/jzus.B130025824903996
   PubMed Web of Science ®Google Scholar
• Tu J, Yu Y, Liu W, Chen S. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2015;9(1):17–24. doi:10.3892/etm.2014.206325452770
   PubMed Web of Science ®Google Scholar
• Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977–1984. doi:10.1038/bjc.2014.48325211663
   PubMed Web of Science ®Google Scholar
• Seo AN, Kwak Y, Kim DW, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One. 2014;9(5):e98528. doi:10.1371/journal.pone.009852824879338
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–746. doi:10.1016/S1470-2045(16)00150-927108243
   PubMed Web of Science ®Google Scholar
• Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol. 2015;21(5):1595–1605. doi:10.3748/wjg.v21.i5.159525663779
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Venook AP, Cederquist L,et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(3):370–398. doi:10.6004/jnccn.2017.0036
   Google Scholar
• Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;11(1):1–6. doi:10.1186/1471-2407-11-27721194487
   PubMed Web of Science ®Google Scholar
• Sun SJ, Lin Q, Sun Q, et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J Cancer Res Ther. 2016;12(2):323–333. doi:10.4103/0973-1482.15408127072259
   PubMed Web of Science ®Google Scholar
• Laurentpuig P, Balogoun R, Cayre A, et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann Oncol. 2016;27(6):4590–4597.
   Google Scholar
• Stahler A, Heinemann V, Neumann J, et al. Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. Anticancer Drugs. 2017;28(7):717–722. doi:10.1097/CAD.000000000000051028582279
   PubMed Web of Science ®Google Scholar
• McKeown E, Nelson DW, Johnson EK, et al. Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer. 2014;5(1):31–43. PMID: 24396496. doi:10.7150/jca.798724396496
   PubMed Web of Science ®Google Scholar
• Chapusot C, Martin L, Mungra N, et al. Sporadic colorectal cancers with defective mismatch repair display a number of specific morphological characteristics: relationship between the expression of hMLH1 and hMSH2 proteins and clinicopathological features of 273 adenocarcinomas. Histopathology. 2003;43(1):40–47. doi:10.1046/j.1365-2559.2003.01641.x12823711
   PubMed Web of Science ®Google Scholar
• Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 2015;15(3):181–194. doi:10.1038/nrc387825673086
   PubMed Web of Science ®Google Scholar
• Michailidi C, Papavassiliou AG, Troungos C. DNA repair mechanisms in colorectal carcinogenesis. Curr Mol Med. 2012;12(3):237–246. doi:10.2174/15665241279921885922082485
   PubMed Web of Science ®Google Scholar
• Mecklin JP. Frequency of hereditary colorectal carcinoma. Gastroenterology. 1987;93(5):1021–1025. doi:10.1016/0016-5085(87)90565-82820826
   PubMed Web of Science ®Google Scholar
• Edelbrock MA, Kaliyaperumal S, Williams KJ. Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. Mutat Res. 2013;743-744:53–66. PMID: 23391514; PMCID: PMC3659183. doi:10.1016/j.mrfmmm.2012.12.00823391514
   PubMed Web of Science ®Google Scholar
• van der Klift HM, Mensenkamp AR, Drost M, et al. Comprehensive mutation analysis of PMS2 in a large cohort of probands suspected of lynch syndrome or constitutional mismatch repair deficiency syndrome. Hum Mutat. 2016;37(11):1162–1179; PMID: 27435373. doi: 10.1002/humu.2305227435373
   PubMed Web of Science ®Google Scholar
• Seifert M, Reichrath J. The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Histol. 2006;37(5–7):301–307. doi:10.1007/s10735-006-9062-517080293
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. doi:10.1056/NEJMoa05230616236737
   PubMed Web of Science ®Google Scholar
• Otsu H, Oki E, Ikawa-Yoshida A, et al. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Res. 2015;35(4):2441–2446. PMID: 25862912.25862912
   PubMed Web of Science ®Google Scholar
• Lu Y, Jingyan G, Baorong S, Peng J, Xu Y, Cai S. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark. 2012;11(5):219–226. PMID: 23220854. doi:10.3233/CBM-2012-0028223220854
   PubMed Web of Science ®Google Scholar
• Ellina MI, Bouris P, Aletras AJ, Theocharis AD, Kletsas D, Karamanos NK. EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules. Biochim Biophys Acta. 2014;1840(8):2651–2661. PMID: 24792576. doi:10.1016/j.bbagen.2014.04.01924792576
   PubMed Web of Science ®Google Scholar
• Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E. Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate. Clin Cancer Res. 2020;26(1):11–17. PMID: 31383734; PMCID: PMC6942620. doi:10.1158/1078-0432.CCR-18-085631383734
   PubMed Web of Science ®Google Scholar
• Yan WY, Hu J, Xie L, et al. Prediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population. Onco Targets Ther. 2016;9:7415–7424. doi:10.2147/OTT.S11708927994472
   PubMed Web of Science ®Google Scholar
• Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117(1):123–131. PMID: 10381918; PMCID: PMC4343206. doi:10.1016/s0016-5085(99)70558-510381918
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia Group B protocol 89803. J Clin Oncol. 2009;27(11):1814–1821; PMID: 19273709; PMCID: PMC2668707. doi: 10.1200/JCO.2008.18.207119273709
   PubMed Web of Science ®Google Scholar